Kenji Kabashima

May 22, 2024 | medscape.com | Andreas Wollenberg |Matthias Augustin |Kenji Kabashima

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Atopic dermatitis (AD) is a complex disease with several systemic treatment options evaluated in the 2022 EuroGuiDerm guideline on AD and new data continuing to emerge.

Apr 2, 2024 | onlinelibrary.wiley.com | Emma Guttman-Yassky |Kenji Kabashima |Delphine Staumont-Sallé |Walter K. Nahm

Specific inhibition of interleukin (IL)-13 with tralokinumab reduced cutaneous type 2 inflammation and improved epidermal pathology in adult patients with moderate-to-severe atopic dermatitis (AD). Tralokinumab reduced AD-associated serum biomarkers, including CC-motif chemokine ligand 17, periostin, immunoglobulin E, and IL-22.